Subject: Genelabs Jumps Amid Weakness In Some Large Stocks 
Date: Published: 10/28/92 (23 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    OTC Focus:
    Weakness Hits Some Large OTC Stocks
    Following Last Week's Strong Advance
    ----
    By Sara Calian
    Staff Reporter of The Wall Street Journal

[34 lines irrelevant to AIDS omitted.  -- sysop]
 
    Genelabs Technologies Inc. jumped 2 to 7.  Prudential Securities
 Inc. biotechnology analyst Joseph Edelman reiterated an "aggressive
 buy" rating on the Redwood City, Calif., company.  He said a leading
 AIDS researcher has demonstrated anti-viral activity in cell
 cultures of the AIDS therapy Genelabs is developing, GLQ223.  The
 analyst wouldn't identify the researcher by name.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]